Vitamin K Epoxide Reductase Complex 1 (VKORC1) Haplotypes in Healthy Hungarian and Roma Population Samples

• Daly AK , KingBP: Pharmacogenetics of oral anticoagulants.Pharmacogenetics13 , 247–252 (2003).
   PubMedGoogle Scholar
• Oldenburg J , BevansCG, FreginA, GeisenC, Muller-ReibleC, WatzkaM: Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.Thromb. Haemost.98 , 570–578 (2007).
   PubMed Web of Science ®Google Scholar
• D‘Andrea G , D‘AmbrosioR, MargaglioneM: Oral anticoagulants: pharmacogenetics relationship between genetic and non-genetic factors.Blood Rev.22 , 127–140 (2008).
   PubMed Web of Science ®Google Scholar
• El Rouby S , MestresCA, LaDucaFM, ZuckerML: Racial and ethnic differences in warfarin response.J. Heart Valve Dis.13 , 15–21 (2004).
   PubMed Web of Science ®Google Scholar
• Kamali F : Genetic influences on the response to warfarin.Curr. Opin. Hematol.13 , 357–361 (2006).
   PubMed Web of Science ®Google Scholar
• Sconce EA , KamaliF: Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.Eur. J. Haematol.77 , 457–462 (2006).
   PubMed Web of Science ®Google Scholar
• Wadelius M , PirmohamedM: Pharmacogenetics of warfarin: current status and future challenges.Pharmacogenomics J.7 , 99–111 (2007).
   PubMed Web of Science ®Google Scholar
• Schalekamp T , BrasseBP, RoijersJF et al.: VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.Clin. Pharmacol. Ther.81 , 185–193 (2007).
   PubMed Web of Science ®Google Scholar
• Oldenburg J , WatzkaM, RostS, MullerCR: VKORC1: molecular target of coumarins.J. Thromb. Haemost.5(Suppl. 1) , 1–6 (2007).
   PubMed Web of Science ®Google Scholar
• Gage BF , LeskoLJ: Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.J. Thromb. Thrombolysis.25 , 45–51 (2008).
   PubMed Web of Science ®Google Scholar
• Rieder MJ , ReinerAP, GageBF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.N. Engl. J. Med.352 , 2285–2293 (2005).
   PubMed Web of Science ®Google Scholar
• Geisen C , WatzkaM, SittingerK et al.: VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation.Thromb. Haemost.94 , 773–779 (2005).
   PubMed Web of Science ®Google Scholar
• Li T , ChangCY, JinDY, LinPJ, KhvorovaA, StaffordDW: Identification of the gene for vitamin K epoxide reductase.Nature427 , 541–544 (2004).
   PubMed Web of Science ®Google Scholar
• Rost S , FreginA, IvaskeviciusV et al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.Nature427 , 537–541 (2004).
   PubMed Web of Science ®Google Scholar
• Carlquist JF , HorneBD, MuhlesteinJB et al.: Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.J. Thromb. Thrombolysis22 , 191–197 (2006).
   PubMed Web of Science ®Google Scholar
• Aquilante CL , LangaeeTY, LopezLM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Clin. Pharmacol. Ther.79 , 291–302 (2006).
   PubMed Web of Science ®Google Scholar
• D‘Andrea G , D‘AmbrosioRL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood105 , 645–649 (2005).
   PubMed Web of Science ®Google Scholar
• Wadelius M , ChenLY, DownesK et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose.Pharmacogenomics J.5 , 262–270 (2005).
   PubMed Web of Science ®Google Scholar
• Yuan HY , ChenJJ, LeeMT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.Hum. Mol. Genet.14 , 1745–1751 (2005).
   PubMed Web of Science ®Google Scholar
• Sconce EA , KhanTI, WynneHA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.Blood106 , 2329–2333 (2005).
   PubMed Web of Science ®Google Scholar
• Nadasi E , GyurusP, CzakoM et al.: Comparison of mtDNA haplogroups in Hungarians with four other European populations: a small incidence of descents with Asian origin.Acta Biol. Hung.58 , 245–256 (2007).
   PubMed Web of Science ®Google Scholar
• Semino O , PassarinoG, Quintana-MurciL et al.: MtDNA and Y chromosome polymorphisms in Hungary: inferences from the palaeolithic, neolithic and Uralic influences on the modern Hungarian gene pool.Eur. J. Hum. Genet.8 , 339–346 (2000).
   PubMed Web of Science ®Google Scholar
• Gresham D , MorarB, UnderhillPA et al.: Origins and divergence of the Roma (Gypsies).Am. J. Hum. Genet.69 , 1314–1331 (2001).
   PubMed Web of Science ®Google Scholar
• Morar B , GreshamD, AngelichevaD et al.: Mutation history of the roma/gypsies.Am. J. Hum. Genet.75 , 596–609 (2004).
   PubMed Web of Science ®Google Scholar
• McKee M : The health of gypsies.BMJ315 , 1172–1173 (1997).
   PubMedGoogle Scholar
• Hajioff S , McKeeM: The health of the Roma people: a review of the published literature.J. Epidemiol. Community Health54 , 864–869 (2000).
   PubMed Web of Science ®Google Scholar
• Kalaydjieva L , GreshamD, CalafellF: Genetic studies of the Roma (Gypsies): a review.BMC Med. Genet.2 , 5 (2001).
   PubMedGoogle Scholar
• Mastana SS , PapihaSS: Origin of the Romany gypsies – genetic evidence.Z. Morphol. Anthropol.79 , 43–51 (1992).
   PubMedGoogle Scholar
• Sadee W , DaiZ: Pharmacogenetics/genomics and personalized medicine.Hum. Mol. Genet.14(Spec. No. 2) , R207–R214 (2005).
   PubMed Web of Science ®Google Scholar
• Dang MT , HambletonJ, KayserSR: The influence of ethnicity on warfarin dosage requirement.Ann. Pharmacother.39 , 1008–1012 (2005).
   PubMed Web of Science ®Google Scholar
• Gan GG , TehA, GohKY, ChongHT, PangKW: Racial background is a determinant factor in the maintenance dosage of warfarin.Int. J. Hematol.78 , 84–86 (2003).
   PubMed Web of Science ®Google Scholar
• Scott SA , EdelmannL, KornreichR, DesnickRJ: Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.Am. J. Hum. Genet.82 , 495–500 (2008).
   PubMed Web of Science ®Google Scholar
• Osman A , EnstromC, ArbringK, SoderkvistP, LindahlTL: Main haplotypes and mutational analysis of vitamin K epoxide reductase ( VKORC1) in a Swedish population: a retrospective analysis of case records.J. Thromb. Haemost.4 , 1723–1729 (2006).
   PubMed Web of Science ®Google Scholar
• Oner OG , LangaeeTY, FengH et al.: VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.Eur. J. Clin. Pharmacol.64 , 889–894 (2008).
   PubMed Web of Science ®Google Scholar
• Lee SC , NgSS, OldenburgJ et al.: Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population.Clin. Pharmacol. Ther.79 , 197–205 (2006).
   PubMed Web of Science ®Google Scholar
• Obayashi K , NakamuraK, KawanaJ et al.: VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.Clin. Pharmacol. Ther.80 , 169–178 (2006).
   PubMed Web of Science ®Google Scholar
• Kimura R , MiyashitaK, KokuboY et al.: Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.Thromb. Res.120 , 181–186 (2007).
   PubMed Web of Science ®Google Scholar
• Wang TL , LiHL, TjongWY et al.: Genetic factors contribute to patient-specific warfarin dose for Han Chinese.Clin. Chim. Acta396 , 76–79 (2008).
   PubMed Web of Science ®Google Scholar
• Harrington DJ , UnderwoodS, MorseC, ShearerMJ, TuddenhamEG, MumfordAD: Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.Thromb. Haemost.93 , 23–26 (2005).
   PubMed Web of Science ®Google Scholar
• Bodin L , VerstuyftC, TregouetDA et al.: Cytochrome P450 2C9 ( CYP2C9) and vitamin K epoxide reductase ( VKORC1) genotypes as determinants of acenocoumarol sensitivity.Blood106 , 135–140 (2005).
   PubMed Web of Science ®Google Scholar
• Spreafico M , LodigianiC, van Leeuwen Y et al.: Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics9 , 1237–1250 (2008).
   PubMed Web of Science ®Google Scholar
• Loebstein R , DvoskinI, HalkinH et al.: A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.Blood109 , 2477–2480 (2007).
   PubMed Web of Science ®Google Scholar

▪ Websites

• National Biobank Network of Hungary www.biobank.hu
   Google Scholar
• Pan-European Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) www.bbmri.eu
   Google Scholar
• National Center for Biotechnology Information www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=9923231ReferenceSNP(refSNP)ClusterReport:rs9923231
   Google Scholar
• National Center for Biotechnology Information:Reference SNP(refSNP)Cluster Report:rs7294 http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7294
   Google Scholar
• National Center for Biotechnology Information: Reference SNP(refSNP) Cluster Report: rs17708472 www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=17708472
   Google Scholar
• Warfarin dosing homepage www.warfarindosing.org/Source/Home.aspx
   Google Scholar
• Perlegen www.perlegen.com
   Google Scholar